Phone:: +1 877 302 8632
Fax:: +1 888 205 9894 (Toll-free)
E-Mail:: orders@antibodies-online.com

For best experience we recommend to activate Javascript in your browser.

SirtAct (CAY-10591)

Act 839699-72-8 2-Amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

/ (SirtAct (CAY-10591))

1 image

Catalog No. ABIN7233290

$130.00

Plus shipping costs $50.00

Shipping to: United States

Delivery in 2 to 5 Business Days

Quick Overview for SirtAct (CAY-10591) (ABIN7233290)

Application

Activation (Act)

Chemical Name

2-Amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

Purpose

SIRT1 activator

Characteristics

Sirt1 activator (233 % at 10 μM)1 Suppresses TNFα release from THP-1 cells and stimulates adipogenesis in 3T3L1 cells1. SIRT1 stimulation by SirtAct leads to decreased tissue factor mediated thrombogenicity in mice2. Inhibits NFκB activation and reduces inflammatory cytokine production in lamina propria mononuclear cells from IBD patients3. Prevents and cures experimental colitis in a mouse model3.

Purity

>98 %

Formula

C20H25N5O2

Solubility

Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 20 mg/ml).
Geldanamycin- FITC
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Radicicol
Inh 12772-57-5

Geldanamycin- Biotin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Herbimycin A
Inh 70563-58-5 [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

17-GMB-APA-GA
Inh [(3R,5S,6R,7S,10S,11S)-21-[3-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]propylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

TEMPO
Inh 2564-83-2 2,2,6,6-Tetramethylpiperidine 1-oxyl, 2,2,6,6-Tetramethyl-1-piperidinyloxy, free radical, (2,2,6,6-Tetramethyl-1-piperidinyl)oxidanyl, 1,1,5,5-tetramethylpentamethylene nitroxide, 2,2,6,6-Tetramethylpiperidine-1-oxyl

Triacsin C
Inh 76896-80-5 (3E)-1-Oxo-3-[(2E,4E,7E)-2,4,7-undecatrien-1-ylidene]triazane

TPCK
Inh 402-71-1 N-(4-Chloro-3-oxo-1-phenyl-2-butanyl)-4-methylbenzenesulfonamide

Staurosporine
Inh 62996-74-1 (2S,3R,4R,6R)-3-Methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one

Application Notes

Optimal working dilution should be determined by the investigator.

Restrictions

For Research Use only
Format

Powder

Storage

-20 °C

Storage Comment

-20°C
Background

CAY10591,Posttranslational modification,Epigenetics,Chromatin,Protein deacetylase,Diabetes,Inflammation,Cytokine,NFkappaB

Molecular Weight

367.46

CAS-No

839699-72-8

You are here: